Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18525 ↗At a glance
Vergleichsstudie in Alimentary Pharmacology & Therapeutics, 2025. Written by Hashem B El-Serag and 13 co-authors. Institution: Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Major MEDLINE topics: Antiviral Agents, Carcinoma, Hepatocellular, Liver Neoplasms, Liver Cirrhosis. Cited 7 times so far (Crossref); 45 references. Funded by: NIDDK NIH HHS, DAA PASS Hep C Consortium, Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center.
Abstract (original language)
Background
Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)–infected patients with cirrhosis who received interferon (IFN)‐free direct‐acting antiviral (DAA) therapy relative to patients who received IFN‐containing therapy or remained untreated.
Aims
To estimate the risk of de novo HCC with DAA treatment in cirrhotic HCV patients compared to no anti‐HCV treatment and those treated with IFN‐based therapy.
Methods
We identified patients with chronic HCV infection and compensated cirrhosis in the US Department of Veterans Affairs healthcare system treated with IFN (2005 to 2013) or DAAs (2013 to 2017). We compared the risk of de novo HCC for patients treated with DAAs, IFN‐containing regimens or no treatment after accounting for differences in demographics, alcohol and drug abuse, comorbidities, laboratory values, healthcare utilisation, prior HCV treatment and HCC surveillance.
Results
A total of 53,847 patients contributed to untreated time, 27,147 patients contributed to DAA‐treated time (15,641 contributed to both untreated and DAA‐treated times) and 6809 patients contributed to IFN‐treated time. HCC risk associated with DAA treatment was significantly lower than untreated [adjusted HR: 0.70 (95% CI: 0.65–0.74)]. The risk of HCC was not significantly different for patients treated with DAA compared with those treated with IFN [adjusted HR: 0.98 (95% CI: 0.87–1.10)].
Conclusions
The study shows a reduced risk of de novo HCC among patients with chronic HCV–related compensated cirrhosis who received DAA treatment compared to that of untreated patients. There were no differences in HCC risk between DAA‐treated and IFN‐treated patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
- Merck & Co., Inc., Rahway, New Jersey, USA.
- AbbVie Inc., North Chicago, Illinois, USA.
- Gilead Sciences, Inc., Foster City, California, USA.
ORCID profiles: Jennifer R Kramer
Funding
- NIDDK NIH HHS
- DAA PASS Hep C Consortium
- Veterans Administration Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center
- Cancer Prevention and Research Institute of Texas
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
El-Serag, H. B., Duong, H., Luster, M., Kanwal, F., Hill, D. D., Burroughs, M., Hernandez, C., Haber, B. A., Larsen, L. M., Marcinak, J. F., Wegrzyn, L. R., Yu, X., Richardson, P., & Kramer, J. R. (2025). Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18525
Vancouver
El-Serag HB, Duong H, Luster M, Kanwal F, Hill DD, Burroughs M, et al. Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18525
BibTeX
@article{ElSerag2025,
author = {El-Serag, Hashem B and Duong, Hao and Luster, Michelle and Kanwal, Fasiha and Hill, Deanna D and Burroughs, Margaret and Hernandez, Candido and Haber, Barbara A and Larsen, Lois M and Marcinak, John F and Wegrzyn, Lani R and Yu, Xian and Richardson, Peter and Kramer, Jennifer R},
title = {Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18525}
}
EUVIMED